

- 18 -

*Sub-A2*  
What is claimed is:

1. A method of monitoring a cancer in a patient which has not metastasized for the onset of metastasis comprising:
  - 5 (a) identifying a patient having a cancer that is not known to have metastasized;
  - (b) periodically analyzing a sample of bodily fluid from the patient for PLA<sub>2</sub>; and
  - (c) detecting levels of PLA<sub>2</sub> in the sample of
- 10 bodily fluid obtained from the patient, wherein elevated levels of PLA<sub>2</sub> in a sample of bodily fluid are indicative of a cancer which has metastasized.
2. The method of claim 1 wherein the bodily fluid is serum.
- 15 3. The method of claim 1 wherein the analysis of the bodily fluid for PLA<sub>2</sub> is by ELISA.
4. The method of claim 3 wherein the established enzyme immunoassay cutoff is 4.5 ng/ml.
- 20 5. The method of claim 1 wherein the cancer is breast, colorectal, ovarian, prostate or testicular cancer.
6. A method of diagnosing a metastatic cancer in a patient comprising:
  - 25 (a) obtaining a sample of biological fluid from a patient; and
  - (b) detecting the level of PLA<sub>2</sub> in a sample of biological fluid, wherein elevated levels of PLA<sub>2</sub> in the sample are indicative of a metastatic cancer.
7. The method of claim 6 wherein the bodily fluid is serum.

- 19 -

8. The method of claim 6 wherein the analysis of the bodily fluid for PLA<sub>2</sub> is by ELISA.

9. The method of claim 8 wherein the established enzyme immunoassay cutoff is 4.5 ng/ml.

*Subj* 10. A method of diagnosing ovarian or testicular cancer in a patient comprising:

(a) obtaining a sample of biological fluid from a patient; and

(b) detecting levels of PLA<sub>2</sub> in the sample; 10 wherein elevated levels of PLA<sub>2</sub> in the sample are indicative of cancer.

*Ab D1* 11. The method of claim 10 wherein the biological fluid is serum.

12. The method of claim 10 wherein PLA<sub>2</sub> is detected 15 by ELISA.

13. A method of monitoring progression, remission, response to therapy and stabilization of prostate, breast, ovarian or testicular cancer in a patient comprising measuring PLA<sub>2</sub> levels in biological fluid samples obtained from a patient 20 at selected times wherein an increase in the measured levels of PLA<sub>2</sub> over time is indicative of progressive cancer, a decrease in the measured levels of PLA<sub>2</sub> over time is indicative of remission or response to therapy of the cancer, and no change in the measured levels of PLA<sub>2</sub> over time is indicative 25 of stabilization of the cancer.

14. The method of claim 13 wherein the bodily fluid is serum.

- 20 -

15. The method of claim 13 wherein PLA<sub>2</sub> is measured  
by ELISA.

*Add D2*